SCHEMBL1099766

SCHEMBL1099766

O=S(=O)(c1ccccc1)N(Cc1ccccn1)c1cc2ccccc2s1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.41
TRPM8 Q7Z2W7 2/20 0.41
KCNA5 P22460 2/20 0.41
CXCR3 P49682 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PTGER2 P43116 2/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099311 0.82 ALDH1A1 (0.48) KMT2AALDH1A1SMN1; SMN2GAATRPM8
SCHEMBL15948196 0.82 PKM (0.51) KMT2AALDH1A1SMN1; SMN2TRPM8KDM4E
SCHEMBL1098953 0.79 NR1D1 (0.47) ALDH1A1SMN1; SMN2PTGER2PDE4APDE4B
SCHEMBL1099837 0.77 TAS2R14 (0.43) KMT2AALDH1A1SMN1; SMN2TRPM8CXCR3
SCHEMBL1097662 0.77 APOBEC3A (0.43) KMT2AALDH1A1SMN1; SMN2GAATRPM8
SCHEMBL1097602 0.77 PKM (0.54) KMT2AALDH1A1SMN1; SMN2CXCR3
SCHEMBL1099363 0.76 CA2 (0.38) KMT2AALDH1A1TRPM8KDM4EHSD17B10
SCHEMBL1098896 0.75 MEN1 (0.45) KMT2AALDH1A1SMN1; SMN2TRPM8CXCR3
SCHEMBL1099102 0.75 TAS2R14 (0.46) KMT2AALDH1A1SMN1; SMN2TRPM8KDM4E
SCHEMBL1099459 0.75 MEN1 (0.45) KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KMT2A 1231/4885ALDH1A1 3091/4885SMN1; SMN2 643/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KMT2A 1231/4885ALDH1A1 3091/4885SMN1; SMN2 643/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KMT2A 1231/4885ALDH1A1 3091/4885SMN1; SMN2 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.